Elnour Asim Ahmed, Raja Nadia Sarfaraz, Abdi Fatemeh, Mostafiz Fariha, Elmubarak Razan Isam, Khalil Alaa Mohsen, Hait Khawla Abou, Alqahtani Mariam Mohamed, Dabbagh Nour, Abdulnasser Zainab, Albek Danah, Amer Abdelfattah, Damook Nosayba Othman Al, Shayeb Aya, Alblooshi Sara, Samir Mohammed, Hajal Abdallah Abou, Barakani Nora Al, Balbahaith Rahf, Mazrouie Hamda Al, Ali Rahaf Ahmed
PhD, MSc. Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Abu Dhabi campus, Abu Dhabi-United Arab Emirates. AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates.
Fourth year student, College of Pharmacy, Al Ain University, Abu Dhabi campus, Abu Dhabi-United Arab Emirates.
Pharm Pract (Granada). 2022 Jul-Sep;20(3):2713. doi: 10.18549/PharmPract.2022.3.2713. Epub 2022 Sep 1.
Shortening the process of prescribing via permitting the pharmacist to select the most appropriate pharmaceuticals for each particular patient may provide great opportunities for pharmacists to develop suitable pharmaceutical care plan, monitor and follow up prescribed medications, communicate and consult physicians for more confirmations.
The objective of the current protocol for the systematic review and meta-analysis of pharmacists prescribing interventions was to explore, investigate the evidence, assess and compare PICO in patients with medical conditions (population), receiving pharmacist's prescribing care services (interventions) versus non-pharmacist's prescribing (comparators), and identify how it will impact the clinical, humanistic, and economic patient's outcomes (outcomes).
The necessary elements of PRISMA will be strictly followed to report the systematic review. The meta-analysis will be reported in line with the Cochrane guidelines for synthesis of trials and all forms will be based on quality measures as per the validated Cochrane templates. We will present the results of the systematic review and the meta-analysis based on PICO comparison between the included trials.
We have identified four models of pharmacist prescribing interventions (independent, dependent [collaborative], supplementary, and emergency prescribing). The results will contain a systematic critical evaluation of the included trials in terms of the sample number of the population (characteristics), the type of interventions and the comparators, and the main outcome measures.
This protocol will report the evidence and explore the magnitude of impact of pharmacist prescribing interventions, on clinical, humanistic, and economic outcomes. .
通过允许药剂师为每个特定患者选择最合适的药物来缩短开药流程,可能为药剂师制定合适的药学服务计划、监测和跟进所开药物、与医生沟通和咨询以获得更多确认提供巨大机会。
当前药剂师开药干预措施系统评价和荟萃分析方案的目的是探索、调查证据、评估和比较患有疾病的患者(人群)、接受药剂师开药护理服务(干预措施)与非药剂师开药(对照)的PICO,并确定其将如何影响患者的临床、人文和经济结局(结局)。
将严格遵循PRISMA的必要要素来报告系统评价。荟萃分析将按照Cochrane试验合成指南进行报告,所有形式将基于经过验证的Cochrane模板的质量衡量标准。我们将根据纳入试验之间的PICO比较呈现系统评价和荟萃分析的结果。
我们确定了四种药剂师开药干预模式(独立、依赖[协作]、补充和紧急开药)。结果将包括对纳入试验在人群样本数量(特征)、干预措施类型和对照以及主要结局指标方面的系统批判性评价。
本方案将报告证据,并探索药剂师开药干预措施对临床、人文和经济结局的影响程度。